OPTIMALIZATION OF THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION

Optimalization of thrombolytic therapy for acute myocardial infarction can be achieved at the site of the causal coronary lesion and at the myocardium at risk. Acute percutaneous transluminal coronary angioplasty does not seem to be advisable as a routine, and the search for the best thrombolytic agent or regimen is ongoing. Aspirin and perhaps heparin prevent early reinfarction. The myocardium at risk should be protected by acute beta-blockade. The role of vasodilating agents, including angiotensin-converting enzyme inhibitors, in this field is still under investigation.